| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |